Your browser doesn't support javascript.
loading
High Rate of Positive Circumferential Resection Margin in Colon Cancer: A National Appraisal and Call for Action.
Healy, Mark A; Peacock, Oliver; Hu, Chung-Yuan; Bednarski, Brian K; Tillman, Matthew M; Messick, Craig; Kaur, Harmeet; Chang, George J.
Afiliación
  • Healy MA; Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
  • Peacock O; Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
  • Hu CY; Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
  • Bednarski BK; Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
  • Tillman MM; Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
  • Messick C; Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
  • Kaur H; Department of Abdominal Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Chang GJ; Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
Ann Surg ; 276(6): 1023-1028, 2022 12 01.
Article en En | MEDLINE | ID: mdl-33630474
ABSTRACT

OBJECTIVE:

To identify rates of positive circumferential resection margin (CRM) for colon cancer surgery in the US. SUMMARY BACKGROUND DATA CRM is one of the most important determinants of local control in colorectal cancers. The extent to which CRM involvement exists after colon cancer surgery is unknown.

METHODS:

Colon cancer cases with resection 2010 to 2015 were identified from the National Cancer Data Base. Adjusting for patient and tumor characteristics, comparisons were made between cases with CRM > 1 mm (negative margin) and those with margin involved with tumor or ≤ 1 mm (positive margin, CRM+). Hospital-level analysis was performed, examining observed-to-expected CRM+ rates.

RESULTS:

In total, 170,022 cases were identified 150,291 CRM- and 19,731 CRM+ (11.6%). Pathologic T-category was the greatest predictor of CRM+, with higher rates in pT4(25.8%), pT4A(24.7%), and pT4B(31.5%) versus pT1(4.5%), pT2(6.3%) and pT3 (10.9%, P < 0.001). Within pT4 patients, predictors of CRM+ included signet-ring histology (38.1% vs 26.7% nonmucinous, and 26.9% mucinous adenocarcinoma, P < 0.001), removing < 12 lymph nodes (36.5% vs 26.1% >12, P < 0.001), community facilities (32.7%) versus academic/research (23.6%, P < 0.001), year (30.1% 2010 vs 22.6% 2015, P < 0.001), and hospital volume (24.5% highest quartile vs 32.7% lowest, P < 0.001). Across 1288 hospitals, observed-to-expected ratios for CRM+ ranged from 0 to 7.899; 429 facilities had higher than expected rates.

CONCLUSIONS:

Overall rate of CRM+ in US colon cancer cases is high. Variation exists across hospitals, with higher than expected rates in many facilities. Although biology is a major influencing factor, CRM+ rates represent an area for multidisciplinary improvement in quality of colon cancer care.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Recto / Procedimientos Quirúrgicos del Sistema Digestivo / Adenocarcinoma / Neoplasias del Colon / Adenocarcinoma Mucinoso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Recto / Procedimientos Quirúrgicos del Sistema Digestivo / Adenocarcinoma / Neoplasias del Colon / Adenocarcinoma Mucinoso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Año: 2022 Tipo del documento: Article